Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The FDA has approved three GLP-1s in particular for both type 2 diabetes treatment and weight loss: Liraglutide (Saxenda, Victoza): While effective, this once-daily injection generally leads to more modest weight loss compared to newer options (its been around since 2014)
Are there opportunities for product expansion or product tailoring to these users
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Are doctor consultations included
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis
Maintaining open communication with your healthcare team ensures safe, effective treatment and allows for timely adjustments to your diabetes management plan
US$ 21.13
US$ 21.39
US$ 27.55
US$ 22.76
